These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

988 related articles for article (PubMed ID: 15464849)

  • 1. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
    Bower JF; Green TD; Ross TM
    Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies.
    Bower JF; Li Y; Wyatt R; Ross TM
    Vaccine; 2006 Jun; 24(26):5442-51. PubMed ID: 16621193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies.
    Young KR; Teal BE; Brooks Y; Green TD; Bower JF; Ross TM
    AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1259-68. PubMed ID: 15588348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Independent but not synergistic enhancement to the immunogenicity of DNA vaccine expressing HIV-1 gp120 glycoprotein by codon optimization and C3d fusion in a mouse model.
    Liu F; Mboudjeka I; Shen S; Chou TH; Wang S; Ross TM; Lu S
    Vaccine; 2004 Apr; 22(13-14):1764-72. PubMed ID: 15068860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d.
    Bower JF; Yang X; Sodroski J; Ross TM
    J Virol; 2004 May; 78(9):4710-9. PubMed ID: 15078953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C3d enhances immune responses using low doses of DNA expressing the HIV-1 envelope from codon-optimized gene sequences.
    Bower JF; Sanders KL; Ross TM
    Curr HIV Res; 2005 Apr; 3(2):191-8. PubMed ID: 15853723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of antibody responses to purified HIV-1 gp120 glycoproteins fused with the molecular adjuvant C3d.
    Koch M; Frazier J; Sodroski J; Wyatt R
    Virology; 2005 Sep; 340(2):277-84. PubMed ID: 16051303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d.
    Green TD; Montefiori DC; Ross TM
    J Virol; 2003 Feb; 77(3):2046-55. PubMed ID: 12525639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes.
    McBurney SP; Young KR; Ross TM
    Virology; 2007 Feb; 358(2):334-46. PubMed ID: 17011011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of gp120-specific protective immune responses by genetic vaccination with linear polyethylenimine-plasmid complex.
    Garzón MR; Berraondo P; Crettaz J; Ochoa L; Vera M; Lasarte JJ; Vales A; Van Rooijen N; Ruiz J; Prieto J; Zulueta J; González-Aseguinolaza G
    Vaccine; 2005 Feb; 23(11):1384-92. PubMed ID: 15661387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting.
    Richmond JF; Mustafa F; Lu S; Santoro JC; Weng J; O'Connell M; Fenyö EM; Hurwitz JL; Montefiori DC; Robinson HL
    Virology; 1997 Apr; 230(2):265-74. PubMed ID: 9143282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mouse strain-dependent differences in enhancement of immune responses by C3d.
    Toapanta FR; Ross TM
    Vaccine; 2004 Apr; 22(13-14):1773-81. PubMed ID: 15068861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigenic properties of a transport-competent influenza HA/HIV Env chimeric protein.
    Ye L; Sun Y; Lin J; Bu Z; Wu Q; Jiang S; Steinhauer DA; Compans RW; Yang C
    Virology; 2006 Aug; 352(1):74-85. PubMed ID: 16725170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA vaccine expressing HIV-1 gp120/immunoglobulin fusion protein enhances cellular immunity.
    Shimada M; Yoshizaki S; Jounai N; Kondo A; Ichino M; Ryo A; Okuda K
    Vaccine; 2010 Jul; 28(31):4920-7. PubMed ID: 20566393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins.
    Ross TM; Xu Y; Green TD; Montefiori DC; Robinson HL
    AIDS Res Hum Retroviruses; 2001 Jun; 17(9):829-35. PubMed ID: 11429124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 DNA vaccine efficacy is enhanced by coadministration with plasmid encoding IFN-alpha.
    Jiang W; Ren L; Jin N
    J Virol Methods; 2007 Dec; 146(1-2):266-73. PubMed ID: 17868910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins.
    Mascola JR; Sambor A; Beaudry K; Santra S; Welcher B; Louder MK; Vancott TC; Huang Y; Chakrabarti BK; Kong WP; Yang ZY; Xu L; Montefiori DC; Nabel GJ; Letvin NL
    J Virol; 2005 Jan; 79(2):771-9. PubMed ID: 15613305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of conformation on the neutralizing antibody response to HIV-1 gp120.
    Steimer KS; Haigwood NL
    Biotechnol Ther; 1991; 2(1-2):63-89. PubMed ID: 1726963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polygene DNA vaccine induces a high level of protective effect against HIV-vaccinia virus challenge in mice.
    Shinoda K; Xin KQ; Jounai N; Kojima Y; Tamura Y; Okada E; Kawamoto S; Okuda K; Klinman D; Okuda K
    Vaccine; 2004 Sep; 22(27-28):3676-90. PubMed ID: 15315847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.